🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsLab Results & BiomarkersGGT as a liver health marker — anyone have experience?

GGT as a liver health marker — anyone have experience?

robert_kc Wed, Sep 10, 2025 at 3:49 AM 24 replies 1,412 viewsPage 1 of 5
This thread is more than 9 months old. Information may be outdated. Consider searching for more recent discussions.
robert_kc
Member
289
1,234
Oct 2024
Kansas City, MO
Sep 10, 2025 at 3:49 AM#1

This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.

The liver data is among the strongest non-weight findings in the class. The semaglutide MASH programme reported a large advantage over placebo on MASH resolution, with a substantial minority also achieving fibrosis improvement — and fibrosis is the endpoint that predicts outcomes. Mechanistically it is reduced hepatic lipogenesis, increased fatty-acid oxidation, less hepatic inflammation, and possibly a direct effect on stellate-cell activation.

Where I think it is weakest: the comparator does most of the work in how this gets reported, and it is not the comparator most people think they are citing.

What I am after is whether normalised enzymes tell you anything about fibrosis, and what the right follow-up measurement is. I would rather have one careful answer than five confident ones.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
17 12PurityPaulOR, MaxMetOK, MounjBrad and 14 others
Reply Quote Save Share Report
Dr.ObesityLA
VIP Member
3,567
19,876
Dec 2023
Los Angeles, CA
Sep 10, 2025 at 4:44 AM#2
robert_kc said:
The liver data is among the strongest non-weight findings in the class.

Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

Baseline: "Moderate hepatic steatosis, liver span 17.2cm, echogenic texture consistent with fat infiltration"
Month 8: "Mild steatosis, liver span 15.8cm, improved echogenicity"
Month 14: "Minimal to no steatosis, normal liver span 14.5cm, normal echotexture"

My liver literally shrank and de-fattened. The ultrasound tech said she's seen this pattern increasingly in GLP-1 patients and it's remarkable how consistently the fatty liver resolves.

16 11KarenAZ_mom, zoe_NC, Dr.ObesityLA and 13 others
Reply Quote Save Share Report
KevinCompounds
VIP Member
5,432
18,234
Dec 2023
Nevada
Sep 10, 2025 at 5:39 AM#3
robert_kc said:
The liver data is among the strongest non-weight findings in the class.

NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy. The Phase 2b data for semaglutide showed 59% NASH resolution (vs 17% placebo) with 43% achieving fibrosis improvement[1].

Mechanism: GLP-1R activation reduces hepatic lipogenesis, increases fatty acid oxidation, reduces hepatic inflammation, and may directly reduce hepatic stellate cell activation (fibrosis pathway).

With resmetirom (thyroid hormone receptor agonist) recently approved for NASH, the field is evolving rapidly. Combination approaches (GLP-1 + resmetirom) are being explored.

References:
[1] Newsome PN, et al. N Engl J Med. 2021;384(12):1113-1124.
15 10MikeKY_noInsulin, Dr.RaviCardio, jennifer_SEA and 12 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
pat_auckland
Member
345
1,567
Jun 2024
Auckland, NZ
Sep 10, 2025 at 6:34 AM#4
KevinCompounds said:
NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.

Liver enzyme update related to liver and MASH: I had mildly elevated ALT/AST at baseline (likely NAFLD). After 11 months on GLP-1 therapy:

MarkerBaselineCurrentNormal Range
ALT60277-56 U/L
AST532110-40 U/L
GGT70339-48 U/L
ALP1007744-147 U/L

FibroScan also improved — liver stiffness from 10.5 kPa to 6.2 kPa. The evidence for GLP-1 agonists in NAFLD/NASH is very promising.

14 9MeganSA_TX, LarryQC_SD, wanda_boise and 11 others
Reply Quote Save Share Report
AttorneyGrant
Member
567
2,890
Apr 2024
Washington, DC
Sep 10, 2025 at 11:45 AM#5
Dr.ObesityLA said:
Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

Adding a me-too, because a thread of one person's experience is not much use. Posting only so the count is not one.

13 8Dr.GastroMayo, JakeBK_lifts, DerekSJ_a1c and 10 others
Reply Quote Save Share Report
1235

Similar Threads

Optimal lab testing frequency on GLP-1 — evidence-based schedule5 replies
A1C from 7.2 to 5.1 — my bloodwork transformation19 replies
Thyroid function monitoring on GLP-1 — TSH and free T4 trends3 replies
Lipid panel improvements mega-thread — share your numbers19 replies
Liver enzymes trending down on GLP-1 — ALT/AST normalization17 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register